Efficacy and Safety during the Combination Therapy of Imipramine and Desmopressin in Primary Monosymptomatic Nocturnal Enuresis.
- Author:
Yong Hoon PARK
1
;
Ji Hyun YEO
;
Jung Youn CHOI
;
Hyo Seok CHUNG
;
Kyung Soo LEE
;
Cheol Woo KO
;
Kyo Sun KIM
;
Kee Hyuk KIM
;
Jung Soe KIM
;
Mee Kyung NAMGOONG
;
Young Seo PARK
;
Ki Soo PAI
;
Kee Hwan YOO
;
Kyung Yil LEE
;
Dae Yeol LEE
;
Seung Joo LEE
;
Oh Kyung LEE
;
Jae Seung LEE
;
Hong Jun LEE
;
Seung Hee JUNG
;
Woo Yeong CHUNG
;
Tae Sun HA
Author Information
1. Department of Pediatrics, College of Medicine Yeungnam University, Daegu, Korea. yhpark@med.yu.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Primary monosymptomatic nocternal enuresis;
Imipramine;
Desmopressin;
Combination therapy
- MeSH:
Appetite;
Child;
Deamino Arginine Vasopressin*;
Enuresis;
Female;
Humans;
Imipramine*;
Nocturnal Enuresis*;
Physical Examination
- From:Journal of the Korean Society of Pediatric Nephrology
2004;8(2):129-137
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Nocternal enuresis is a common disorder. Tricyclic antidepressant and desmopressin have been accepted pharmacological treatment for this disorder. We conducted a cooperative study to investigate the efficacy and adverse reactions of imipramine, desmopressin and combination treatment in children with primary monosymptomatic nocturnal enuresis(PMNE). METHODS: Data from a large multicenter study were analysed. In the period of 8 months in 2002, the study comprised of 168 children(78 boys and 90 girls, 5 to 15 years old) with PMNE for imipramine, desmopressin or combination treatment. Before treatment a history, physical examination and laboratory tests were performed and the children were observed for 2 weeks. Response rate, adverse reactions and enuresis episodes after stopping drug administration were evaluated after 12-weeks of imipramine, desmopressin or combination of both. RESULTS: After 4 weeks, the frequency of bed wetting in all treated patients decreased during treatment significantly. Even though a 30-50% reduction in the number of wet nights were 68.6%, 74.4% and 86.1% during 12 weeks treatment by imipramine, desmopressin and both of them respectively, there was no significant difference between them. The most common adverse reaction was decreased appetite from imipramine administration. But no serious drug-related adverse events were reported. CONCLUSION: Efficacy of the combination therapy of imipramine and desmopressin in PMNE appears not to be better than either drug alone. It is necessary to pay attention on account of adverse reactions during imipramine treatment even though imipramine and desmopressin were generally well tolerated.
